Orthocell (ASX:OCC) submitted a 510(k) application with the US Food and Drug Administration to sell its Remplir nerve repair device in the US market, according to a Thursday filing with the Australian bourse.
The submission is based on a regulatory study of Remplir, which met all the endpoints and provided key data to support the application, the filing said.
The 90-calendar day review process is expected to start between March and April 2025, with commercial distribution expected soon after, the filing said.
Shares fell nearly 5% in midday trade Thursday.
Price (AUD): $1.20, Change: $-0.06, Percent Change: -4.78%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。